Ohio State Navbar

Directory

Susan Geyer, PhD


Staff photo

B306 Starling Loving Hall
320 West 10th Avenue
Columbus, OH 43210

Phone: (614) 366-4122

Email: geyer.58@osu.edu

 

Current OSU Appointment

Associate Professor, Hematology

 

Editorial Activities

2000 - 2007 Statistics in Medicine
2000 - 2007 Lifetime Data Analysis
2000 - 2007 Journal of Planning and Statistical Inference
2000 - 2007 Controlled Clinical Trials
2004 - present Journal of Clinical Oncology
2004 - 2006 M.S Comprehension exams conducted through the Clinical Training Research Program
 

Honors

0 - 1989 Congressional Nomination. West Point.
1994 - 1995 Patricia Roberts Harris Fellow. U.S Department of Education.
1995 Outstanding Graduate Student Award. Washington Statistical Society.
 

Journal Articles

Salerian AJ, Deibler WE, Vittone BJ, Geyer SM, et al.. "Sildenafil for Psychotropic-induced Sexual Dysfunction in 31 Woman and 61 Men." Journal of Sex and marital Therapy. Vol. 2, no. 26. (January 2000.): 133-140.

Jelinek DF, Tschumper RC, Geyer SM , Bone ND, Dewald GW, Hanson CA, Stenson, MJ, Witzig TE, Gerreri A, Kay NE. "Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia." BR J Haematol. Vol. 115, no. 4. (December 2001.): 854-861.

Colon-Otero G, Niedringhause RD, Hillman S, Geyer, Susan , Sloan JA, Krook JE, Windschilt HE, Marks RS, Wiesenfeld M, Tschetter LK. "A Phase II Trial of Edatrexate, 6+ Vinblastine, Adriamycin, Cisplatin and Filgrastim (EVAC/G-CSF) In Patients with Advanced Non-Small Cell Carcinoma of the Lungs : A North Central Cancer Treatment Group Trial." American Journal of Clinical Oncology. Vol. 24, no. 6. (December 2001.): 551-555.

Yoong K, Kurtin PJ, Allmer C, Geyer S , Habermann TM, Nagorney DM, Witzig TE. "Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma." Leukemia Lymphoma. Vol. 42, no. 6. (November 2001.): 1235-1241.

Tefferi A, Li CY, Reeder CB, Geyer SM , Allmer C, Levitt R, Michalak J, Aldo F, Krook JE, Witzig TE, Schaefer PL, Mailliard JA.. "A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia." Leukemia. Vol. 15, no. 8. (August 2001.): 1171-1175.

Rajkumar SV, Dispenzieri A, Fonesca R, Lacy MW, Geyer, SM , Lust, JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE. "Thalidomide for Previously Untreated Indolent or Smoldering Multiple Myeloma." Leukemia. Vol. 15, no. 8. (August 2001.): 1274-1276.

Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MA, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallef IN, Geyer SM , Markovic SN,. "Early Lymphocyte Recovery Predicts Superior Survival After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma or Non-hodgkin Lymphoma." Blood. Vol. 98, no. 3. (August 2001.): 579-585.

Porrata LF, Ingle JN, Lizow MR, Geyer SM , Markovic SN. "Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer." Bone Marrow Transplant. Vol. 28, no. 9. (November 2001.): 865-71.

Rajkumar,S,V; Hayman,S; Gertz,M,A; Dispenzieri,A; Lacy,M,Q; Greipp,P,R; Geyer,S; Iturria,N; Fonseca,R; Lust,J,A; Kyle,R,A; Witzig,T,E. "Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma." JOURNAL OF CLINICAL ONCOLOGY. Vol. 20, no. 21. (November 2002.): 4319-4323.

Schild SE, Stella PJ, Geyer SM , Bonner JA, Marks RS, McGinnis WL, Goetz SP, Kuross SA, Mailliard JA, Kugler JW, Schaefer PL, Jett JA. "Phase III Trial Comparing Chemotherapy Plus Once-Daily Radiotherapy in Stage III Non-small Celll Lung Cancer." International Journal of Radation Oncology, Biology, Physics. Vol. 54, no. 2. (October 2002.): 370-378.

Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM , Markovic SN. "Early Lymphocyte Recovery is a Predictive Factor for Prolonged Survival After Autologous Hematopoietic Stem Cell Transplantation for Accute Myelogenous Leukemia." Leukemia. Vol. 16, no. 7. (July 2002.): 1311-1318.

Cox,L,S; Sloan,J,A; Patten,C,A; Bonner,J,A; Geyer,S,M; McGinnis,W,L; Stella,P,J; Marks,R,S. "Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancer." PSYCHO-ONCOLOGY. Vol. 11, no. 6. (November 2002.): 472-478.

Sanderson Cox L, Sloan JA, Patten CA, Bonner JA, Geyer SM , McGinnis WL, Stella PJ, Marks RS. "Smoking Behavior of 226 Patients with the Diagnosis of Stage IIIA/IIIB Non-small Cell Lung Cancer." Psycho-Oncology. Vol. 6, no. 11. (January 2002.): 472-8.

Gertz MA, Lacy MQ, Dispenzieri A, Cheson BD, Barlogi B, Kyle RA, Palladini G, Geyer SM , Merlini G. "A multicenter phase II trial of 4 '-iodo-4 ' deoxydoxorubicin (IDOX) in primary amyloidosis (AL)." Amyloid. Vol. 9, no. 1. (March 2002.): 24-30.

Elliot MA, Mesa RA, Li CY, Hook CC, Ansell SM, Levitt RM, Geyer SM , Tefferi A. "Thaliodmide Treatment in Myelofibrosis with Myeloid Metaplasia." British Journal of Haematology. Vol. 117, no. 2. (May 2002.): 288-296.

Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM , Markovic SN. "Early Lymphocyte Recovery is a Predictive Factor for Prolonged Survival After Autologuous Hematopoietic Stem Cell Transplantation is Associated with Better Survival in Hodgkin's Disease." British Journal Haematology. Vol. 117, no. 3. (June 2002.): 629-633.

Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM , Dewald GW, Hanson CA, Jelinek DF. "B-CLL Cells are Capable of Synthesis and Secretion of Both Pro and Antiangiogenic Molecules." Leukemia. Vol. 16, no. 5. (May 2002.): 911-919.

Schild SE, Stella PJ, Geyer SM , Bonner JA, McGinnis WL, Mailliard JA, Brindle J, Jatoi A, Jett JR. "The Outcome of Combined-Modality Therapy for Stage III Non-Cell-Lung Cancer in the Elderly." Journal of Clinical Oncology. Vol. 17, no. 21. (September 2003.): 3201-6.

Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM , Iturria NL, Fonseca R, Hayman SR, Lust JA, Kyle RA, Greipp PR, Witzig TE, Rajkumar SV. "Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma." MAYO CLINIC PROCEEDINGS. Vol. 78, no. 1. (January 2003.): 34-39.

Rajkumar,S,V; Gertz,M,A; Lacy,M,Q; Dispenzieri,A; Fonseca,R; Geyer,S,M; Iturria,N; Kumar,S; Lust,J,A; Kyle,R,A; Greipp,P,R; Witzig,T,E. "Thalidomide as initial therapy for early-stage myeloma." LEUKEMIA. Vol. 17, no. 4. (April 2003.): 775-779.

Howe R, Micallef INM, Inwards DJ, Ansell SM, Dewald GW, Dispenzieri A, Gastineau DA, Gertz MA, Geyer SM , Hanson CA, Lacy MQ, Tefferi A, Litzow MR. "Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma." Bone Marrow Transplantation. Vol. 32, no. 3. (August 2003.): 317-324.

Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S , Wiesenfeld M, Jett JR. "Weekly Carboplatin and Paclitaxel in Elderly Non-Small-Cell Lung Cancer Patients (>65 Years of Age): A Phase II North Central Cancer Treatment Group Study." American Journal of Clinical Oncology. Vol. 26, no. 5. (October 2003.): 441-447.

Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Witzig TE, Fonseca R, Lust JA, Greipp PR, Kyle RA, Gertz MA. "Poor Tolerance to High Doses of Thalidomide in Patients with Primary Systemic Amyloidsis." Amyloid. Vol. 4, no. 10. (January 2003.): 257-61.

Adjei AA, Mauer A, Bruzek L, Marks RS, HIllman S, Geyer S , Hanson LJ, Wright JJ, Erlichamn C, Kaufmann SH and Vokes EE. "Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients with Advanced Non-Small-Cell Lung Cancer." Journal of Clinical Oncology. Vol. 21, no. 9. (May 2003.): 1760-1766.

Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM , Witzig TE, Fonseca R, Lust JA, Greipp PR, Kyle RA, Gertz MA. "Poor Tolerance to High Doses of Thalidomide in Patients with Primary Systemic Amyloidosis." AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS. Vol. 10, no. 4. (December 2003.): 257-261.

Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. "Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL)." Blood. Vol. 101, no. 10. (May 2003.): 3801-3808.

Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, King BF, Geyer SM. "Prostate Volume Measurement by Transrectal Ultrasound and Computed by Tomogrpahy Before and After Permanent Prostate Brachytherapy." International Journal of Radiation Oncology Biology Physics. Vol. 60, no. 3. (November 2004.): 767-776.

Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S , Allmer C, Witzig, TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. "Single Agent Dexamethasone for Pre-Stem Cell Transplant Induction Therapy for Multiple Myeloma." Bone Marrow Transplant. Vol. 6, no. 34. (January 2004.): 485-490.

Fink SR, Patermoster SF, Smoley SA, Flynn HC, Geyer SM , Shanafelt TD, Lee YK, Jelinek DF, Kay NE, Dewald GW. "Fluorescent-labeled DNA Probes Applied to Novel Biological Aspects of B-Cell Chronic Lymphocytic Leukemia." CLL. (January 2004.): -.

Kanard A, Jatoi A, Castillo R, Geyer S, Schulz TK, Fitch TR, Rowland KM, Nair S, Krook JE, Kugler JW. "Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity." Lung Cancer. Vol. 43, no. 3. (March 2004.): 345-353.

Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer SM , Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA. "High-Dose Therapy and Autologous Stem Cell Transplantation for Mulitple Myeloma Poorly Responsive to Intial Therapy." Bone Marrow Transplantation. Vol. 34, no. 2. (July 2004.): 161-167.

30. Abraham RS, Geyer SM, Ramirez-Alvarado M, Price-Troska TL, Gertz MA, Fonseca. "Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL)." JOURNAL OF CLINICAL IMMUNOLOGY. Vol. 24, no. 4. (July 2004.): 340-353.

Shanafelt TD, Geyer SM , Kay NE. "Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL." Blood. Vol. 103, no. 4. (February 2004.): 1202-1210.

Porrata LF, Gertz MA, Geyer SM , Litzow MR, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DA, Markovic SN. "The Dose of Infused Lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma." Leukemia. Vol. 18, no. 6. (June 2004.): 1085-1092.

Schild SE, Bonner JA, Shanhan TG, Brooks BJ, Marks RS, Geyer SM , HIllman SL, Farr GH Jr., Tazelaar HD, Krook JE, Geoffroy FJ, Salim M, Arusell RM, Mailliard JA, Schaefer PL, Jett JR. "Long-Term Results of a Phase III Trial Comparing Once-Daily Radiotherapy with Twice-Daily Radiotherapy in Limited-stage Small-Cell Lung Cancer." International Journal of radiation Oncology Biology Physics. Vol. 4, no. 59. (January 2004.): 943-51.

Fink SR, Paternoster SF, Smoley SA, Flynn HC, Geyer SM , Shanafelt T, Lee YK, Jelinek DF, Kay NE, Dewald GE. "Fluorecent-labeled DNA Probes Applied to Novel Biological Aspects of B-Cell Chronic Lymphocytic Leukemia." Leukemia Research. Vol. 29, no. 3. (March 2005.): 253-262.

Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM , Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle Ra, Witzig RE, Gertz MA. "Combination Therapy with Lenalidomide Plus Dexamethsone (REV/DEX) for Newly Diagnosed Myeloma." Blood. Vol. 106, no. 13. (December 2005.): 4050-4053.

Witzig TE, Vukov AM, Habermann TM, Geyer SM , Kurtin PJ, Friedenburg WR, White WL, Chalchal HI,Flynn PJ, Fitch TR, Welker DA. "Rituximab Therapy for Patients with Newly Diagnosed, Advanced Stage, Follicular Grade I Non-Hodgkin's lymphom: A Phase II Trial in the North Central Cancer Treatment Group." Journal of Clincial Oncology. Vol. 23, no. 6. (February 2005.): 1103-1108.

Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM , McGregor C. "Prognostic Factors in Patients with Post-Transplant Lymphoprliferative Disorders (PTLD) in the Rituximab Era." Leukemia and Lymphoma. Vol. 46, no. 2. (February 2005.): 191-196.

Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM , Ristow KM, Larson TS,l Walker RC, Ansell SM, Macon WR, Gores GG, Stegall MD, McGregor CG. "Prognostic Analysis for Survival in Adult Solid Organ Transplant Recipients with Post-Transplantation Lymphoproliferative Disorders." Journal of Clinical Oncology. Vol. 23, no. 30. (October 2005.): 7574-7582.

Shanafelt TD, Lee YK, Bone ND, Strege AK, Narayanan VL, Sausville EA, Geyer SM , Kaufmann SH, Kay NE. "Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine." Blood. Vol. 6, no. 34. (January 2005.): 485-490.

Markovick SN, Geyer SM , Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C. "A Phase II Study of Bortezomib in the Treatment of Metastatic Malignant Melanoma." Cancer. Vol. 12, no. 103. (January 2005.): 2584-2589.

Witzig TE, Geyer SM , Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, GRoss H, Haufmann SH. "Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma." Journal of Clinical Oncology. Vol. 23, no. 23. (August 2005.): 5347-5356.

Markovick SN, Geyer SM , Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C. "A Phase II Study of Bortezomib in the Treatment of Metastatic Malignant Melanoma." Cancer. Vol. 103, no. 12. (June 2005.): 2584-2589.

Joao C, Ogle BM, Geyer S. "Immunoglobulin Promotes the Diversity and the Function of T Cells." European Journal of Immunology. Vol. 36, no. 7. (January 2006.): 1718-1728.

Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM , Greipp PR, Rajkumar SV, Kimlinger T, Lust JA, Fonseca R, Allred J, Witzig TE. "A Phase II Trial of Imatinib in Patients with Refractory/Relapsed Myeloma." Leukemia & Lymphoma. Vol. 47, no. 1. (January 2006.): 39-42.

Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S , Inwards DJ, White WL, Habermann TM. "A Pilot Study of Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma." Cancer. Vol. 107, no. 12. (January 2006.): 2826-32.

Ansell SM, Geyer SM , Maurer MJ, Kurtin PJ, Micallef IN, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE. "Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients." Clinical Cancer Resources. Vol. 20 pt 1, no. 15. (January 2006.): 6056-63.

Molina,Julian,R; Nikcevich,Daniel; Hillman,Shauna; Geyer,Susan; Drevyanko,Timothy; Jett,James; Verdirame,Joseph; Tazelaar,Henry; Rowland,Kendrith; Wos,Edward; Kutteh,Leila; Nair,Suresh; Fitch,Tom; Flynn,Patrick; Stella,Philip; Adjei,Alex,A. "A phase IINCCTG study of irinotecan and docetaxel in previously treated patients with non-small cell lung cancer." CANCER INVESTIGATION. Vol. 24, no. 4. (June 2006.): 382-389.

Moreno-Aspitia A; Colon-Otero G; Hoering A; Tefferi A; Niedringhaus RD; Vukov A; Li CY; Menke DM; Geyer SM; Alberts SR. "Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.." Cancer. Vol. 107, no. 4. (August 2006.): 767-.

Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE. "Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.." Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 12, no. 20 Pt 1. (October 2006.): 6056-.

Goel A, Dispenzieri A, Geyer SM , Greiner S, Peng KW, Russell SJ. "Synergistic Activity of the Proteasome Inhibitor PS-341 with Non-Myeloablative 153-EDTMP Skeletally Targeted Radiotherapy in an Orthotopic Model of Multiple Myeloma." Blood. Vol. 10, no. 107. (January 2006.): 4063-70.

Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S , Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. "Prospective Evaluation of Clonal Evolution During Long-term Follow-up of Patients with Untreated Early-Stage Chronic Lymphocytic Leukemia." Journal of Clinical Oncology. (January 2006.): -.

Goel A; Dispenzieri A; Geyer SM; Greiner S; Peng KW; Russell SJ. "Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma.." Blood. Vol. 107, no. 10. (May 2006.): 4063-4070.

Dispenzieri A; Gertz MA; Lacy MQ; Geyer SM; Fitch TR; Fenton RG; Fonseca R; Isham CR; Ziesmer SC; Erlichman C; Bible KC. "Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.." Haematologica. Vol. 91, no. 3. (March 2006.): 390-393.

Browning,Rebekah,L; Geyer,Susan,M; Johnson,Amy,J; Jelinek,Diane,E; Tschumper,Renee,C; Call,Timothy,G; Shanafelt,Tait,D; Zent,Clive,S; Bone,Nancy,D; Dewald,Gordon,W; Lin,Thomas,S; Heerema,Nyla,A; Grever,Michael,R; Kay,Neil,E; Byrd,John,C; Lucas,David,M. "Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia." LEUKEMIA RESEARCH. Vol. 31, no. 12. (December 2007.): 1737-1740.

Shanafelt TD; Lin T; Geyer SM; Zent CS; Leung N; Kabat B; Bowen D; Grever MR; Byrd JC; Kay NE. "Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.." Cancer. Vol. 109, no. 11. (June 2007.): 2291-2298.

Cerhan JR; Wang S; Maurer MJ; Ansell SM; Geyer SM; Cozen W; Morton LM; Davis S; Severson RK; Rothman N; Lynch CF; Wacholder S; Chanock SJ; Habermann TM; Hartge P. "Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival.." Blood. Vol. 109, no. 12. (June 2007.): 5439-5446.

Mesa RA, Camoriano JK, Geyer SM , Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. "A Phase II Trial of Tipifarnib in Myelofibrosis: Primary, Post- Polycthemic Vera and Post-Essential Thrombocythemia." Leukemia. Vol. 21, no. 9. (September 2007.): 1964-1970.

Nowakowski GS; Hoyer JD; Shanafelt TD; Geyer SM; LaPlant BR; Call TG; Jelinek DF; Zent CS; Kay NE. "Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: A universally available prognostic test." MAYO CLINIC PROCEEDINGS. Vol. 82, no. 4. (April 2007.): 449-453.

Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Bergsagel PL, Stewart AK, Rajkumar SV. "Long-term Results of Response to Therapy, Time to Progression, and Survival with Lenalidomide Plus Dexmethasone in Newly Diagnosed Melanoma." Mayo Clincal Procedures. Vol. 82, no. 10. (October 2007.): 1179-1184.

Dispenzieri A; Lacy MQ; Zeldenrust SR; Hayman SR; Kumar SK; Geyer SM; Lust JA; Allred JB; Witzig TE; Rajkumar SV; Greipp PR; Russell SJ; Kabat B; Gertz MA. "The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.." Blood. Vol. 109, no. 2. (January 2007.): 465-470.

Kurtz DM; Tschetter LK; Allred JB; Geyer SM; Kurtin PJ; Putnam WD; Rowland KM Jr; Wiesenfeld M; Soori GS; Tenglin RC; Bernath AM; Witzig TE. "Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.." Leukemia & Lymphoma. Vol. 48, no. 7. (July 2007.): 1290-1298.

Browning RL; Geyer SM; Johnson AJ; Jelinek DF; Tschumper RC; Call TG; Shanafelt TD; Zent CS; Bone ND; Dewald GW; Lin TS; Heerema NA; Grever MR; Kay NE; Byrd JC; Lucas DM. "Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.." Leukemia Research. Vol. 31, no. 12. (December 2007.): 1737-.

Martin W; Abraham R; Shanafelt T; Clark RJ; Bone N; Geyer SM; Katzmann JA; Bradwell A; Kay NE; Witzig TE. "Serum-free light chain - a new biomarker for patients with B-cell non-Hodgkin lymphocytic leukemia." TRANSLATIONAL RESEARCH. Vol. 149, no. 4. (April 2007.): 231-235.

Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC. "Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.." Blood. Vol. 109, no. 2. (January 2007.): 405-411.

Habermann TM; Wang SS; Maurer MJ; Morton LM; Lynch CF; Ansell SM; Hartge P; Severson RK; Rothman N; Davis S; Geyer SM; Cozen W; Chanock SJ; Cerhan JR. "Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era.." Blood. Vol. 112, no. 7. (October 2008.): 2694-2702.

Brown GG; Dian BC; Douglass KO; Geyer SM; Shipman ST; Pate BH. "A broadband Fourier transform microwave spectrometer based on chirped pulse excitation.." The Review Of Scientific Instruments. Vol. 79, no. 5. (May 2008.): 053103-.

Witzig,Thomas,E; Geyer,Susan,M; Kurtin,Paul,J; Colgan,Joseph,P; Inwards,David,J; Micallef,Ivana,NM; LaPlant,Betsy,R; Michalak,John,C; Salim,Muhammad; Dalton,Robert,J; Moore,Dennis,F; Reeder,Craig,B. "Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group." LEUKEMIA & LYMPHOMA. Vol. 49, no. 6. (June 2008.): 1074-1080.

Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS,. "CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential.." British Journal Of Haematology. Vol. 140, no. 5. (March 2008.): 537-546.

Weiss EA; Porter VJ; Chiechi RC; Geyer SM; Bell DC; Bawendi MG; Whitesides GM. "The use of size-selective excitation to study photocurrent through junctions containing single-size and multi-size arrays of colloidal CdSe quantum dots.." Journal Of The American Chemical Society. Vol. 130, no. 1. (January 2008.): 83-.

Weiss EA; Chiechi RC; Geyer SM; Porter VJ; Bell DC; Bawendi MG; Whitesides GM. "Size-dependent charge collection in junctions containing single-size and multi-size arrays of colloidal CdSe quantum dots.." Journal Of The American Chemical Society. Vol. 130, no. 1. (January 2008.): 74-.

Witzig TE, Geyer SM , Kurtin PJ, Inwards DJ, Michallef IN, Laplant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB. "Salvage Chemotherapy with Rituximab DHAP for Relapsed Non-Hodgkin Lymphoma." Leukemia Lymphoma. Vol. 6, no. 49. (January 2008.): 1074-80.

Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD. "Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.." British Journal Of Haematology. Vol. 141, no. 5. (June 2008.): 607-614.

Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS,. "Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.." The Journal Of Clinical Investigation. Vol. 118, no. 1. (January 2008.): 306-315.

Richardson D, Sugiyama H, Wing S, Sakata R, Grant EJ, Shimizu Y, Nishi N, Geyer S , Soda M, Suyama A, Kasagi F, Kodama K. "Positive Association Between Ionizing Radation and Lymphoma Mortality Among Men." American Journal of Epidemiology. Vol. 8, no. 169. (January 2009.): 969-76.

Awan FT; Kay NE; Davis ME; Wu W; Geyer SM; Leung N; Jelinek DF; Tschumper RC; Secreto CR; Lin TS; Grever MR; Shanafelt TD; Zent CS; Call TG; Heerema NA; Lozanski G; Byrd JC; Lucas DM. "Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.." Blood. Vol. 113, no. 3. (January 2009.): 535-.

Habermann TM, Thompson CA, LaPlant BR, Bauer BA, Janney CA, Clark MM,. "Complementary and alternative medicine use among long-term lymphoma survivors: A pilot study." American Journal Of Hematology. Vol. 84, no. 12. (December 2009.): 795-798.

Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, Geyer SM, Campbell ME, Kyle RA, Rajkumar SV, Greipp PR, Kline MP, Xiong Y, Moon-Tasson LL, Donovan KA. "Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1 beta-Induced Interleukin 6 Production and the Myeloma Proliferative Component." MAYO CLINIC PROCEEDINGS. Vol. 84, no. 2. (February 2009.): 114-122.

Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G. "Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine." Proceedings Of The National Academy Of Sciences Of The United States Of America. Vol. 107, no. 16. (April 2010.): 7473-7478.

Micallef IN, Kahl BS, Mauerer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S , Inwards DJ, White wL, Haabermann TM. "A Pilot Study of Epratuzumab and Rituximab in Combination with Cyc.lophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy in Patients with Previously Untreated, Diffused Large B-Cell Lymphoma." Cancer. Vol. 12, no. 107. (January 2010.): 2826-32.

Shanafelt TD, Lin T, Geyer SM , Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. "Pentostatin, Cyclophosphamide and Rituximab Regimen in Older Patients." Cancer. Vol. 11, no. 109. (January 2010.): 2291-8.

Geyer SM, Morton LM, Habermann TM, Allmer C, Davis S, Cozen W, Severson RK, Lynch CF, Wang SS, Maurer MJ, Hartge P, Cerhan JR. "Smoking, Alcohol Use, Obesity, and Overall Survival From Non-Hodgkin Lymphoma." Cancer. Vol. 116, no. 12. (June 2010.): 2993-3000.

Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA. "A phase II study of Sm-153-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma." American Journal Of Hematology. Vol. 85, no. 6. (June 2010.): 409-413.

Takahashi I, Geyer SM, Nishi N, Ohshita T, Takahashi T, Akahoshi M, Fujiwara S, Kodama K, Matsumoto M. "Lifetime risk of stroke and impact of hypertension: estimates from the adult health study in Hiroshima and Nagasaki." HYPERTENSION RESEARCH. Vol. 34, no. 5. (May 2011.): 649-654.

Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, Costinean S, Pilarski RT, Morrison C, Suren D, Liu J, Chen J, Kamal J, Shapiro CL, Huebner K. "Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features." Breast Cancer Research And Treatment. Vol. 129, no. 2. (September 2011.): 421-432.

Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA. "International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens." AMERICAN JOURNAL OF HEMATOLOGY. Vol. 86, no. 1. (January 2011.): 96-98.

Grant EJ, Neriishi K, Cologne J, Eguchi H, Hayashi T, Geyer S, Izumi S, Nishi N, Land C, Stevens RG, Sharp GB, Nakachi K.. "Associations of Ionizing Radiation and Breast Cancer-Related Serum Hormone and Growth Factor Levels in Cancer-Free Female A-Bomb Survivors." RADIATION RESEARCH. Vol. 176, no. 5. (November 2011.): 678-687.

Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci G.. "DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia." LEUKEMIA. Vol. 26, no. 5. (May 2012.): 1106-1107.

Blum,William; Schwind,Sebastian; Tarighat,Somayeh,S; Geyer,Susan; Eisfeld,Ann-Kathrin; Whitman,Susan; Walker,Alison; Klisovic,Rebecca; Byrd,John,C; Santhanam,Ramasamy; Wang,Hongyan; Curfman,John,P; Devine,Steven,M; Jacob,Samson; Garr,Celia; Kefauver,Cheryl; Perrotti,Danilo; Chan,Kenneth,K; Bloomfield,Clara,D; Caligiuri,Michael,A; Grever,Michael,R; Garzon,Ramiro; Marcucci,Guido. "Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia." BLOOD. Vol. 119, no. 25. (June 2012.): 6025-6031.

 

Reference Works

January 1996 Geyer SM , Christman MC."Forecasting Changes in Ecomonic Time Series" .
January 1998 Culver D, Geyer SM."Visualizing the Health of Cheasapeake Bay" .
January 1998 Geyer SM , Christman MC."Forecasting and Turning Points in Environmental Time Series Under Asymmetric Loss" .
January 1999 Geyer SM , Christman MC."Predicting Spatial Hotspot Regions" .
January 2000 Tschumper RC, Kay NE, Geyer SM , Bone ND, Freeman BK, Dwald GW, Hanson CA, Witzig TE, Jelinek DF."Analysis of Immunoglobulin VH Genes in Relation to CD 38 Expression in B Cell Chronic Lymphocytic Leukemia (B-CLL)" San Francisco. : 716a
January 2000 Tefferi A, Reeder CB, Geyer SM , Allmer C, Li CY, Levitt R, Michalak JC, Addo F, Krook JE, Witzig TE, Schaefer PL, Maillard JA."A Phase II Study of Sequential Combination Chemotherapy with Cyclophosphamide (CTX), Prednisone, and 2-Chlorodeoxyadenosine (2-CDA) in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL)" . : 296b
January 2000 Christman MC, Popowitz (Geyer) SM."Estimating the Area of a Spatial Hotspot" .
January 2000 Sargent DJ, Chan V, Goldbert R, Geyer SM."A Three Outcome Design for Phase II Clincial Trials" .
January 2000 Rajkumar SV, Hayman S, Fonseca R, Dispenzieri A, Lacy MQ, Geyer S , Wellick L, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE,."Thalidomide Plus Dexamethasone (Thal/Dex) and Thalidomide Alone (Thal) as First Line Therapy for Newly Diagnosed Myeloma (MM)" . : 168a
January 2000 Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, Gastineau DA, Dispenzieri A, Ansell SM, Micallfe IM, Geyer SM , Markovic SN."Early Lymphocyte Recovery Predicts Superior Survival After Autologus Hematopoietic Stem Cell Transplantation in Multiple Myeloma or Non-Hodgkin's Lymphoma" .
January 2000 Jelinek DF, Hanson CA, Dewald GW, Witzig TE, Bone ND, Geyer SM , Tefferi A, Stenson MJ, Tschumper RC, Kay NE."Analysis of Immunoglobin (IG) Variable (VH) Region Mutational Status and CD 38 Phenotype for B-CLL Patients Entered on North Central Cancer Chemotherapy Trials Group (NCCTG) Clinical Trials" . : 835a
December 2000 Hanson CA, Dewald GW, Witzig TE, Bone ND, Geyer SM , Tefferi A, Stenson MJ, Tschumper RC, Kay NE."Anaylysis of Immunoglobin (IG) Variable (V) REgion Mutational Status and CD38 Phenotype for B-Cell Patients Entered on North Central Cancer Themochemotherapy Trials Group (NCTTG) Clinical Trials" .
December 2000 Gertz MA, Lacy MQ, Dispenzieri A, Cheson B, Barlogie B, Kyle RA, Palladini G, Geyer S , Melini G,."A Multicenter Phase II Trial of 4'-iodo-4' Deoxydoxorubicin (IDOX) in Primary Amyloidosis (AL)" . : 288 b
January 2001 Kay NE, Bone N, Howell KG, Tschumper RC, Geyer SM, Jenlinek DF."B-chronic Lympocytic Leukemia (CLL) Cells are Capable of Secreting Both Pro and Anti-angiogenic Factors: Implications for Abnormal Angiogensis" . : 23
January 2001 Kay NE, Geyer SM , Hillman DW, Bone ND, Tschumper RC, Howell KH, Hanson CA, Dewald GW, Jelinek DF."Angiogenic Status of Blood B Cells in B-chronic Lymphocytic Leukemia" . : 361 a
January 2001 Tschumper RC, Kay NE, Iturria SJ, Geyer SM , Bone ND, Dewald GW, Hanson CA, Jelinek DF."Gene Expression Profiling of Germline (GL)/D38 (lo), GL/CD38 (hi), Somatic Mutation (SM)/CD38 (lo), and SM/CD38(hi), Subsets of B-CLL" . : 471a
January 2001 Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JH, Elliott MA, Panrdanani SH, Ansell SM, Call TG, Colon-Otero G, Geyer SM , Hanson CA, Dewald GW, Kaufmann SH."Gleevee Therapy in Myclobibrosis and Mycloid Metaphlasia (MMM)." . : 626a
January 2001 Meyer R, Brockman S, Paternoster S, Bone N, James CD, Jelinek D, Tschumper R, Geyer S, Hanson CA, Pruthi R, Witzig TE, Kay N, Dewald G."Fluorescense-labeled DNA Probes to Study Indolent and Aggressive B-CLL: Comparison to Rai Stage Level of Clonal B-cells, LgVh Mutation Status and Conventional Cytogenetic" . : 306a
January 2001 Marks R, Streitz J, Deschamps C, Mahoney M, Geyer SM , Stella P."Response Rate and Toxicity of Pre-operative Placlitaxel (P) and Carboplantin in Patients with Resectable Non-small Cell Lung Cancer" . : 340
January 2001 Geyer SM , Sargent DJ, O'Fallon JR."Single Stage Phase II Design with an Interim Analysis an Alternative to the Two Stage Design" . : 63s
January 2001 Geyer SM , Kay NE, Tschumper RC, Jelinek DF."Analysis Update of Clonal B-cell CD 38 and Immunoglobulin Variable Region Sequence Status in Relation to Clincial Outcome for B-CLL" .
January 2001 Stella P, Marks R, Schild S, Geyer SM , Maillaiard J, Kozelsky T, Geoffroy F, Bonner J."Phase III Trial of Chemotherapy Plus Either Standard Radiotherapy (QD-RT) or Accelerated Hyperfractionated Thoracic Radiotherapy (AHRT) for Stage III Non-small Cell Lung Cancer (NSCLC)" . : 312a
January 2001 Elliott MA, Mesa RA, Li CH, Hook CC, Ansell SM, Levitt R, Geyer SM , Tefferi A."Thalidomide Treatment in Myclofibrosis with Mycloid Metaplasia (MMM)" . : 627a
March 2001 Sargent D, Chan V, Goldbert R, Geyer SM."A Three-outcome design for Phase II Clinical Trials" .
January 2001 Rajkumar SV, Hayman SR, Gertz MA, Dispenzieri A, Lacy M, Greipp PR, Geyer S, Itturia N, Fonseca R, Lust JA, Kyle R, Witzig TE."Combination Therapy with Thalidomide Plus Dexamethasone (Thal/DEX) For Newly diagnosed Myeloma (MM)" . : 849 a
January 2001 Rajkumar SV, Gertz MA, Dispenzieri A, Lacy MQ, Fonseca R, Hayman S, Geyer S, Lust JA, Kyle RA, Greipp PR, Witzig TE."Thalidomide Therapy for Previously Untreated Smoldering and Relapsed Multiple Myeloma (MM)" . : 299a
January 2001 Pruthi R, Stenson M, Geyer S, Iturria N, Witzig TE, Call T, Tefferi A, Kay NE, Lust JA, Phyliky RL."Phase II Trial of Theophylline in Asymptomatic Patients with B-cell Chronic Lymphocytic Leukemia (CLL) Previouly Untreated with Chemotherapy" . : 292 b
January 2001 Porrato LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM."Early Lymphocyte Recovery Is a Predictive Factor For Prolonged Survival after Autologous Hematopoietic Stem Cell Tranplantation for Acute Myleogenous Leukemia" . : 937b
January 2001 Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM , Markovic SN."Early Lymphocyte Recovery is Associated with Better Survival Post-autologous Stem Cell Transplantation in Hodgkin's Disease" .
January 2001 Porrata LF, Ingle JN, Litzow MR, Geyer SM , Markovic SN."Prolonged Survival Associated with Early lymphocyte Recovery After Autologous Hematopoietic Stem Cell Tranplantation for Patients with Metastatic Breast Cancer." . : 9a
January 2001 Johnston PB, Micallef INM, Inwards DJ, Ansell SM, Geyer SM , Iturria NL, Gastineau DA, Litzow MR."Predictive Factors for Unsuccessful Mobilization of Peripheral Blood Stem Cells in Patients with Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma" . : 77
January 2001 Rajkumar SV, Dispenzieri A, Lacy M, Geyer S , Iturria N, Fonseca R, Hayman SR, Lust JA, Kyle R, Greipp PR, Gertz MA, Witzig TE."Response Rate and Durablility with Thalidomide Therapy for Relapsed Multiple Myeloma" . : 162 a
January 2002 Witzig TE, Vukov AM, Habermann TM, Geyer S, Friedenberg WR, White WL, Salim M, Flynn PJ, Fitch TR, Morton RF."Rituximab Therapy for Patients with Newly Diagnosed, Asymptomatic Advanced-Stage Follicular Grade I Non-Hodgking's Lymphoma (NHL): A Phase II Trial in Norht Central Cancer Treatment Group (NCCTG)" . : 361a
January 2002 Wiseman GA, Colgan JP, Inwards DJ, Micallef INM, Porrata LF, Gansen DN, Tuinstra NL, Geyer SM, Witzig TE."Yttrium-90Zevalin Phase I Sequential Dose Radioimmunotherapy Trial Of Patients with Relapsed Low Grade and Follicular B-cell Non-hodgkin's Lymphoma (NHL): Preliminary Result" .
January 2002 Wiseman GA, Colgan JP, Inwards DJ, Micallef INM, Porrata LF, Gansen DN, Tuinstra NL, Geyer SM, Witzig TE."Yittium-90 Zevalin Phase I Dose of Radioimmunotherapy Trial of Patients with Relapsed Low Grade and Follicular B-cell Non-Hodgkins Lymphoma (NHL): Preliminary Results" . : 358a
January 2002 Winkler JM, Dispenzieri A, Lacy M, Geyer S , Rajkumar SV, Witzig T, Greipp PR, Kyle R, Fonseca R, Gertz MA."The Plasma Cell Labeling Index (PCLI) Suprecedes the Prognositic Significance of Karyotypic Chromosome 13 Abnormalities (13) in Multiple Myeloma (MM) Patients Undergoing High-dose Chemotherapy with Stem Cell Support (HD)" . : 269a
January 2002 Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer S, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE."Single-Agent Thalidomide as initial Therapy for Asymptomatic (Smoldering of Indolent) Myeloma" . : 403a
January 2002 Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer S, Iturria N, Kumar S, Lust JA, Kyle RA, Greipp PR, Witzig TE."Single-Agent Thalidomide as Intial Therapy for Asymptomatic (Smolder of Indolent) Myeloma" . : 403a
January 2002 Geyer S."Challenges and Triumphs in Establishing a Multi-Institution Clinical Trials Consortium" .
January 2002 Adjei AA, Mauer A, Marks R, Hillman S, Bruzek LM, Geyer SM , Hanson LJ, Erlichman C, Kaufmann SH, Vokes EE,."A Phase II Study of the Farnesyltransferase Inhibitor R1 15777 in Patients with Advanced Non-small Cell Lung Cancer" . : 290 a
January 2002 Abraham RS, Price-Troska TL, Allmer C, Geyer SM , Kyle RA, Gertz MA, Fonseca R.."Immunoglobin Light Chain Variable (V) Region Gene Usage Determines Organ Tropism and Overall Survival in Light Chain-associated (AL) Amyloidosis" . : A351
January 2002 Abraham RS, Geyer SM , Ramirez-Alvardo M, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R."Immunoglobin Variable (V) Region Germline Genes and Mutational Hotspots Potentially Influences Protien Misfolding in Light Chain Amyloidosis (AL)" . : 603a
January 2002 Abraham RS, Geyer SM , Price-Troska TL, Kyle RA, Gertz MA, Fonseca R."Immunoglobin Light Chain Variable (V) Region Genes Influenced Clinical Presentation and Outcome in Light Chain-Associated (AL) Amyloidosis" .
January 2002 Moreno-Aspitia A, Geyer S , Li CY, Tefferi A, Witzig, Niedrinhaus RD, Vukov AM, Morton R, Fitch T, Addo FE, Dakhil SR, Tschetter L, Colon-Otero G."N998B: Multicenter Phase II trail of Thalidomide (Thai) in Adult Patients with Myelodysplastic Syndromes (MDS)" . : 96a
January 2002 Sande JR, Verdirame J, HIllman S, Geyer S, Drevyanko T, Tazelaar H, Jett J, Adjei AA."A Phase II Study of Irinotecan and Docetaxel in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC)" . : 324 a
January 2002 Lacy MQ, Wettstein P, Gertz MA, Gastineau DA, Greipp PR, Fonseca R, Dispenzieri A, Lust JA, Witzig TE, Rajkumar SV, Geyer SM, Valone F, Kyle RA."Post Autologous Transplantation Consolidation of Mulitple Myeloma with Idiotype-pulsed Antigen Presenting (Dendritic) Cells (APC8020)" . : 31a
January 2002 Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Iturria N, Allmer C, Witzig TE, Lust JA, Greipp PR, Litzow MR, Gertz MA."Single Agent Dexamethasone for Induction in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Tranplantations" . : 432 a
January 2002 Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Itturia N, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA."Autologous Peripheral Blood Stem Cell Transplantation for Primary Refractory Multiple Myeloma" . : 432a
January 2002 Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S , Iturria N, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA."Single Agent Dexamethasone for Induction in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Tranplants" . : 432a
January 2002 Dispenzieri A, Witzig TE, Lacy MQ, Rajkumar SV, Geyer SM, Kimlinger T, Greipp PR, Fonseca R, Lust JA, Gertz MA."A Phase II Trial of Gleevec in Patients with Refactory/Relapsed Myeloma" . : 814a
January 2002 Dispenzieri A, Lacy MQ, Rajkumar V, Geyer SM , Fonseca R, Witzig TE, lust JA, Greipp PR, Kyle RA, Gertz MA."High Doses of Thalidomide Are Not Well Tolerated in Patients with Primary Systemic Amyloidosis" . : 398a
January 2002 Sloan JA, Cella D, Frost MH, Guyatt GH, Sprangers MA, Symonds T,Geyer S."Quality of Life Assessment for Oncology Patients: Assessing the Clinical Significance" . : 503b
January 2002 Milliard JA, Jatoi J, Hillman S, Stella J, Vanone S, Vanon S, Perez EA, Cannon MW,Geyer SM, Weisenfeld M, Jett JR."Weekly Carboplatin and Paclitaxel in Elderly Non-small Cell Lung Cancer Patients (_>65 Years of Age): A Phase II North Central Cancer Treatment Group Study" . : 383 A
January 2002 Herman MG, Pisansky TM, Kruse JJ, Pisciandro JI, Davis BJ, Geyer SM , King BF."Daily On-line Positioning of the Prostate for Three-dimensional Conformal Radiotherapy (3D-CRT) Using an Electronic Portal Imaging Device (EPID)" . : 179
January 2003 Litzow, MR, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ."A Phase I/II Trial of Cladribine (2-CDA), Thiotepa (TT) and Rabbit Antithymocyte Globulin (rATG) as Reduced Intensity Conditioning (RIC) Regimen for Non-myeloablative Allogeneic Perpheral Blood Stem Cell Transplant (NMA-PBSCT) for Hematologic" . : 402b
January 2003 Elliott MA, Geyer SM , Camoriano JK, Kahanic SP, Alexander SJ, Medgyesy DC, Li CY, Tefferi A."A Low Dose Thalidomide (Td) Treament in myelofibrosis with Myeloid Metaplasia (MMM): An NCCTG Study" . : 923a
January 2003 Witzig TE, Wiseman GA, Geyer SM, Colgan JP, Inwards DJ, Micallef IN, Porrata LF, White WL."A Phase I Trial of Two-Sequential Doses of Zevalin Radioimmunotherapy for Relapsed Low-Grade B-Cell Non-Hodgkin's Lymphoma" . : 406a
January 2003 Witzig TE, Geyer SM, Salim M, Inwards DJ, Fonseca R, Kaufman SH, Kurtin P, Colgan JP, Call TG, Moore Jr D, White WL."A Phase II Trial of the Rapamycin Analog CCI-779 in Previously Treated Mantle Cell Non-Hodgkin's Lymphoma Interim Analysis of 18 Patients" . : 643a
January 2003 Witzig TE, Geyer SM Salim M, Inwards DJ, Fonseca R, Kaufmann SH, Kurtin P, Colgan JP, Call TG, Moore D Jr, White WL."A Phase II Trial of the Rapamycin Analog CCI-779 in Previously Treated Mantle Cell Non-Hodgkin's Lymphoma: Interim Analysis of 18 Patients" . : 643a
January 2003 Wiseman GA, Colgan JP, Micallef INM, Porrata LF, Inwards DJ, Whitel WL, Geyer SM, Witzig TE."Interim Safety Results of Phase I Trial of Two Sequential Doses of Yttrium-90 Ibritumomab Tiuxetan for Previously Treated Patiens with Low-grade Non-Hodgkin's Lymphoma (NHL)" . : 575
January 2003 Philip PA, Geyer SM, Thomas JP, Pitot HC, Donehower R, Kim FP, Picus J, Fitch TR, Mahoney MR, Erlichman C."Tolerablility of OSI-774 (Tarceva) in Locally Advanced or Metastatic Hepatocellular (HCC) an Dbiliary (BILI) Carcinomas: An Interim Report" . : 364
January 2003 Lacy MQ, Geyer SM , Foster N, Wettstein P, Dispenzieri A, Gastineau DA, Greipp PR, Fonseca R, Lust J, Witzig T, Rajkumar SV, Zeldenrust S, Peshwa M, Kyle RA, Gertz MA,."Dendritic Cell-Based Idiotype Vaccination for Primary Systematic Amyloidosis" .
January 2003 Ghorbrial IM, Ristow KM, McGregor CG, Geyer SM, Ansell SM, Habermann TM."Rituximab and IPI are Prognostic Indicators in CD20 Positive Post Transplant Lymphoproliferative Disorders (PTLD)" . : 573
January 2003 Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Macon W, Ristow K, Larson T, Ansell SM, Gores G, Stegall M, Walker R, McGregor C."Proposed Prognostic Model for Survival in Solid Organ Transplant Recipients with Post Transplant Lymphoproliferative Disorders (PTLD)" . : 392a
January 2003 Geyer SM , Dispenzieri A, Vesole D, Reece D, Rue M, West P, White M, Abrams J, Medows B."Common Data Elements Development for Myeloma Trials: A Joint Project of the National Cooperative Cancer Clinical Trials Groups and NCI" .
January 2003 Okuno SH, Delaune R, Geyer S, Aubry MC, Reinke D, Dalton R, Rowland KM, Nair S, Mailliard J, Fitch t."Gemcitabine an Epirubicin in Patients with Malignant Pleural Mesothelioma (MPM)" . : 697
January 2003 Dispenzieri A, Wiseman GA, Lacy MQ, Geyer S , Litzow MR, Tefferi A, Inwards DJ, Micallef IN, Gastineau DA, Ansell S, Gertz MA."Preliminary Results from a Phase I/II Study of 153-Samarium EDTMP (153-SM-EDMTP) with Fixed Dose Melphalan Peripheral Stem Cell Transplant (PBSCT) for Multiple Myeloma (MM)" .
January 2003 Micallef INM, Kahl BS, Gayko U, Cesano A, Ansell SM, Colgan JP, Geyer S , Maurer MJ, Inwards DJ, White DJ, White Wl, Horning SJ, Haberman TM."A Pilot Study of Epratuzumab and Rituximab in Combination with CHOP Chemotherapy (ER-CHOP) in Previously Untreated Patients with Diffused Large B-Cell Lymphoma (DLBCL)" . : 643a
January 2003 Mesa RA, Camoriano JK,Geyer SM , Kaufmann SH, Erlichman C, Juckett M, Tefferi A."A Phase II Consortium (P2C) Trial of R11577 (Zarnestra) in Myelofibrosis with Myeloid Metaplasia: Interm Analysis of 18" . : 922a
January 2003 Kay NE, Lin T, Call T, Jelinek DF, Bone ND, Dewald GW, Heerema NA, Tschumper R, Smith L, Geyer SM , Byrd JC."Pentostatin Combination Therapy for Untreated B-Chronic Lymphocytic Leukemia" . : 676a
January 2003 Schulz TK, Geyer SM, Jatoi A, Castillo R, Fitch TR, Dakhil SR, Rowland KM, Nair S, Krook JE, Kugler JW."Oral Vinorelbine in Elderly Patients (> 65 years old) with advanced Non-small Cell Lung Cancer (NSCLC): A Phase II Trial from the North Central Treatment Group" . : 752
January 2003 Schild SE, Stella JP, Geyer SM , Bonner JA, McGinnis WL, Brindle J, Jatoi A, Jett JR."The Outcome of Combination Modality Therapy for Non-Small Cell Lung Cancer (NSCLC) in the Elderly" . : S19
January 2003 Schild SE, Brindle JS, Geyer SM, Krook JE, Kugler JW, Mailliard JA, Schaefer PL, Hillman S, Bonner JA, Jett J."Long Term Results of a Phase III Trial Comparing Once a Day Radiotherapy (qd RT) or Twice a Day Radiotherapy (bid RT) in Limited Stage Small Cell Lung Cancer (LSCLC)" . : S23
January 2003 Schild SE, Brindle JS, Geyer SM, Krook JE, Kugler JW, Mailliard JA, Schaefer PL, Hillman S, Bonner JA, Jett J."Long Term Results of a Phase III Trial Comparinng Once a Day Radiotherapy (qd RT) or Twice a Day Radiotherapy (bid RT) in Limited Stage Small Cell Lung Cancer (LSCLC)" . : S19
January 2003 Schild S, Brindle JS, Geyer SM , Krook JE, Kugler JW, Mailliar JA, Schaeffer PL, Hillman S, Rowland KM, Bonner JA."Long Term Result of a Phase III Trial Comparing Once a Day Radiotherapy (QD RT) or Twice a Day Radiotherapy (BID RT) in Limited Stage Small Cell Lung Cancer (LSCLC)" . : 631
January 2003 Brockman SR, Shanafelt TD, Paternoster SF, Nast DM, Flynn HC, Bone ND, Geyer SM , Croce CM, Phyliky RL, Witzig TE, Kay NE, Dewald GW."Conventional and Novel Fluorescent-Labled DNA Probes to Evaluate Critical Genetic Defects Among Patiens with Early Stage B-CLL" . : 671a
January 2004 Tink S, Geyer S, Shanafelt T, Smoley S, Paternoster S, Giordano K, Tschumper R, Jelinkek D, Bone N, Kabat B, Call T, Phyliky R, Kay N, Dewald G."Clinical Significance of Homozygoous D13S19 Deletion of B-cell Chronic Lympocytic Leukemia (B-CLL)" . : 2799
January 2004 Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Hoering A,Geyer SM, Zeldenrust SR, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE."Combination Therapy with CC-5013 (Lenalidomide; Revlimid) Plus Dexamtheasone (Rev/Dex) for Newly Diagnosed Myeloma (MM)" . : 331
January 2004 Goetz MP, Jatoi A, Geyer SM, Safgren SL, Kuffel MJ, Adjei AA, Castillo RA, Dakhil SR, Fitch TR, Ames MM."MDRI and CYP3A5 Polymorphisms and Clinical Outcome in Elderly Patients Treated with Oral Vinorelbine as First-line Therapy for Metastatic Non-small Cell Lung Cancer" .
January 2004 Geyer SM, Maurer M."Methods for Evaluating T Cell Repertorie (TcR) via CDR3 Spectratyping Analysis" .
January 2004 Geyer SM, Markovic SM, Fitch TR, Albertini MR, Maples WJ, Fracasso PM, Erlichman C."Phase II Study of PS-341 (Bortezomib) in the Treatment of Metastatic Malignant Melanoma (MMM)" . : 716s
January 2004 Philip PA, Mahoney MR, Thomas JP, Pitot HC, Donehower R, Kim GP, Picus J, Fitch TR, Geyer SM, Erlichman C."Phase II Trial of OSI-774 in Patient s with Hepatocellular and Biliary Cancer" . : 174
January 2004 Philip PA, Mahoney MR, Thomas JP, Pitot HC, Donehower R, Kim GP, Picus J, Fitch TR, Geyer SM, Erlichman C."A113 OSI-774 (Tarceva) in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC): A Multicenter Phase II Consortium (P2C) Study" .
January 2004 Philip PA, Mahoney MR, Thomas JP, Pitor R, Donehower R, Kim GP, Picus J, Fitch TR, Geyer SM, Erlichman C."A115 Efficacy and Updated Tolerability of OSI-774 (Tarceva) in Patients with Locally Advanced or Metastatic Billiary (BILI) Carcinoma: A Multi-center Phase II Consortium(P2C) Study" .
January 2004 Philip PA, Mahoney M, Thomas J, Pitot H, Donehower R, Kim G, Picus J, Fitch T, Geyer S, Erlichman C."Phase II Trial of Erlotinib (OSI-774) in Patients with Hepatocellular or Biliary Cancer" . : 4025
January 2004 Ansell SM, Geyer SM, Witzig TE, Jelinek DF, Kurtin PJ, Micallef INM, Stella P, Etzell P, Erlichman C, Novak AJ."NCCTG Trial of Concomaitant or Sequential IL-12 in Combination with Rituzimab in Previous treated Non-Hodgkin's lymphoma Patients" . : 580s
January 2004 Dispenzieri A, Witzig TE, Lacy MQ, Geyer SM, Kimlinger T, Rajkumar V, Greipp PR, Fonseca R, Lust JA, Zeldenrust SR, Hayman SR, Gertz MA."A Phase II Trial of Gleevac in Patients with Refractory/Relapsed Myeloma" . : 2420
January 2004 Dispenzieri A, Lacy MW, Geyer SM, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Rajkumar SV, Kyle RA, Fonseca R, Gertz MA."Low Dose Single Agent Thalidomide Is Tolerated in Patients with Primary Systmeic Amyloidosis, but Responses are Limited" . : 4920
January 2004 Dispenzieri A, Bible KC, Fitch TR, Geyer SM, Fenton R, Fonseca R, Getman CR, Ziesmer SC, Erlichman C, Gertz MA."The Lack of Clinical Efficacy of Flavopiridol in Patients with Relapsed Refractory Myeloma" . : 3461
January 2004 Witzig T, Ansell SM, Geyer SM, Kurtin PJ, Rowland KM, Flynn PJ, Morton RF, Dakhil SR, Gross HM, Maurer MJ, Kaufman SH."Anti-tumor Activity of Low-dose Single Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group" . : 6504
January 2004 Micallef IN, Kalh BBBS, Gayko U, Cesano A, ANsell SM, Geyer S, Inwards DJ, Maurer MJ, Horning S, Habermann TM."Initial Result of a Pilot Study of Epratuzumab and Rituximab in Combination with CHOP Chemotherapy (ER-CHOP) in Previously Untreated Patients with Diffuse Large B-cell Lymphoma (DLBCL)" . : 6580
January 2004 Mesa RA, Camoriano JK, Geyer SM, Kaufmann SH, Rivera CE, Erlichman C, Tefferi A."A Phase II Consoritum (P2C) Trial of R115777 (Tipifarnib) in Myelofibrosis with Myeloid Metaplasia" . : 1509
January 2004 Mandrekar S, Geyer SM M, suman V, Ballman K, Hoering A, Sargent D."Clinical Trial Designs for Dose-seeking Non-MTD with Biomarkers Endpoint" .
January 2005 Zent CS, Bone ND, Geyer SM , Kay NE."Tumor Cells Resistant to Alenmtuzumab Complement Mediated Cytotoxicty in Patients with High Risk Previously Untreated Early Stage CLL: A Possible Mechanism of Treatment Failure" . : 2973
January 2005 Witzig TE, Ansell SM, Geyer, SM, Kurtin PJ, Inwards DJ, Kaufmann SH, Flynn PJ, Morton RF, Dakhil SR, Gross HM, Maurer MJ, Kaufmann SH."Anti-tumor Activity of Low-dose Single Agent CCI-779 for Relapsed Mantel Cell Lymphoma: A Phase II Trial in the North Central Treatment Group" . : 561s
January 2005 Shanafelt TD, Geyer S, Bone N, Schwager S, Lee YK, Nowakowski G, Call TG, Zent CS, Kay NE."Evaluation of the Prognostic Implications of Pro-and Anti-Angiogenic Cytokines in 311 Patients with Untreated Chronic Lymphocytic Leukemia" . : 712
January 2005 Shanafelt TD, Fink S, Witzig TE, Paternoster SF, Smoley S, Stockero K, Flynn HC, Allmer C, Jenkins R, Geyer S, Kay NE, Dewald G."Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-up" . : 2098
January 2005 Sargent DJ, Geyer SM, Lu H."Incorporating Interim Analyses and/or Historical Controls into Flexible Screening Trials" .
January 2005 Sargent DJ, Geyer SM."When Is Statistics Not the Answer: Allowing for Flexibility in Phase II Clinical Trial Design" .
January 2005 Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Greipp PR, Witzig TE, Geyer SM, Moon-Tasson LL, Rajkumar SV, Donovan KA."In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated With Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrated a Significantly Increased Time to Progression (TTP) and a Decreased C-reactiveProtien (CRP) Compared with Nonresponders" . : 2567
January 2005 Habermann TM, Janney CA, Clark MM, Rummans TA, Sloan JA, Cerhan JR, Geyer SM, Thomas RJ."A Pilot Study of Physical Activity Level and Mood Among Long-term Lymphoma Survivors" . : 4692
January 2005 Habermann TM, Bauer BA, Janney CA, Rummans TA, Sloan JA, Clark MM, Geyer SM, Cerhan JR."Beliefs, Attitudes and Utilization of Complementary and Alternative Medicine (CAM) Among Long-Term Lymphoma Survivors: A Pilot Study" . : 4700
January 2005 Tschumper RC, Geyer SM , Shanafelt TD, Kay NE, Mulvhill EM, Jelinek DF."Molecular and Clinical Analysis of a Midwest Cohort of B0CLL Patients Utilizing the Immunoglobulin Vh1-69 Gene" . : 5016
January 2005 Rajkumar SV, Hayman S, Lacy MQ, Dispenzieri A, Geyer SM, Kabat b, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Wtizig TE, Gertz MA."Combination Therpay with Lenalidomide Plus Dexamtheasone (Rev/Dex) for Newly Diagnosed Myeloma" . : 781
January 2005 Porrata LF, Ristow KM,Geyer SM, Markovic SN, Persky DO, Colgan JP, White WL, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM."Absolute Lymphocyte Count Recovery Predicts Superior Survival and is Independent of the International Prognostic Index in Patients with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma" . : 931
January 2005 Goel A, Dispenzieri A, Geyer SM, Greiner S, Russell SJ."Synergistic Activity of the Proteasome Inhibitor PS-341 with Non-Myeloablative 153-Sm-EDTMP in a Syngeneic Orthotopic Model of Multiple Myeloma" . : 3453
January 2005 Geyer SM, Maurer M, Kay NE, Reed A, Strausbach M, Wettstein P."Methods for Evaluating T Cell Receptor (TcR) Repertorie via CDR3 Spectratyping Analysis" .
January 2005 Geyer SM , Sargent DJ, Lu H."Incorporating Interim Analyses and/or Historical Controls into Flexible Screening Trials" .
January 2005 Sloan JA, Clark MM, Janney CA, Rummans TA, Geyer SM, Cerhan JR, Habermann TM."Quality of Life Concerns of Long-term Lymphoma Survivors: Results of a Pilot Study" . : 4695
January 2005 Dispenzieri A, Lacy MQ, Zeldenrust SR, Geyer SM, Lust JA, Hayman SR, Kumar SK, Allred JB, Rajkumar V, Kabat B, Witzig TE, Greipp PR, Russell SR, Ghorbrial I, Gertz MA."Lenalidomide has Activity in a Phase II Trial in Patients with Primary Systemic Amyloidosis" . : 252
January 2006 Zent CS, Bone ND, Call TG, Shanafelt TD,Geyer, SM, Secreto CR, Jelinek DF, Dewald GW, Kay NE."Altemtuzumab and Rituximab for Therapy of Patients with Early Stage High Risk CLL: Report of a Planned Interim Analysis" . : 2829
January 2006 Shanafelt TD, Lee YK,Geyer, SM, Grote D, Stenson M, Zincke S, Ansell SM, Witzig TE, Kay NE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA."Cardiac Biomarkers Predict for Ability To Tolerate and Complete Therapy with Lenalidomide Dexamathosone in AL Amyloidosis" . : 130
January 2006 Shanafelt TD, Byrd JC,Geyer, SM, Bowen D, LaPlant B, Zent CS, Call TG, Kay NE."The Pentostatin, Cyclophosphamide, and Rituximab Regimen (PCR) Is Highly Active and Well Tolerated Regardless of Patient Age, Creatinine Clearance, and Performance Status: Analysis of a Multi-Center Phase II Trial" . : 2785
January 2006 Shanafelt TD, Bone ND,Geyer, SM, LaPlant B, Witzig TE, Schawager S, Dewald GW, Nowakowski GS, Tschumper RC, Zent CS, Call TG, Jelinek DF, Kay NE."Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia" . : 2776
January 2006 Mesa RA, Pardanani A, Steensma DP, Litzow M, Hogan W,Geyer, SM, Wu W, Zeldis J, Tefferi A."A Phase II Study of the Combination of Low-dose Thalidomide, Predisone, and Oral Cyclophosphamide (TPC Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM)" . : 2689
January 2006 Kay N,Geyer, SM, Call T, Shanafelt T, Zent C, Jelinek D, Tschumper R, Bone N, Dewald G, Lin T, Heerema N, Smith L, Grever M, Byrd J."Combination Chemoimmunotherapy with Pentostatin, Cyclophosphamide and Rituximab Shows Signifcant Clinical Activity with Low Accompanying Toxicity in Previously Untreated B-Chronic Lymphocytic Leukemia" . : 35
January 2006 Joao C, Geyer S, Markovic S, Gertz M, Lacy M, Dispenzieri A, Kumar S, Hayman S, Gastineau D, Porrata L."Recovery of Polyclonal Immunoglobin Serum Levels After Autologous Stem Cell Transplantation Predicts Disease Free Survival in Patients with Multiple Myeloma" . : 10088
January 2006 Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, Michalak JC, Salim, M, Nikcevich DA, Dakhil SR, Fitch TR."Salvage Chemotherapy with Rituximab DHAP (RDHAP) for Relapsed Non-Hodgkin Lymphoma (NHL)" . : 7532
January 2006 Hayman S, Gertz M, Lacy M, Dispenzieri A, Fonseca R,Geyer, SM, Kumar S, Zeldenrust S, Russell S, Lust J, Kyle R, Greipp P, Witzig T, Rajkumar SV."Long-term Results of Single-Agent Thalidomide as Initial Therpay for Asymptomatic (Smoldering or Indolent) Myeloma" . : 3568
January 2006 Habermann TM, Wang S, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S,Geyer, SM, Cozem W, Chanock S, Cerhan JR."Germline Single Nucleotide Poymorphoisms (SNPs) in IL1A, IL6, IL10, IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL)" . : 2028
January 2006 Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer, SM, LaPlant B, Call TG, Jelinek DF, Zent CS, Kay NE."Smudge Cells of Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test" . : 2785
January 2006 Lacy M, Gertz M, Dispenzieri A, Hayman S,Geyer, SM, Zeldenrust S, Kumar S, Greipp P, Fonseca R, Lust J, Russell S, Kyle r, Witzig T, Bergsagel L, Rajkumar SV."Lenalidomide Plus Dexamethasone (Rev/Dex) in Newly Diagnosed Myeloma: Response to Therapy, Time to Progression, Survival" . : 798
January 2006 Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV, Kimlinger T, Lust JA, Fonseca R, Allred J, Witzig TE."A Phase II Trial of Imatinib in Patients with Refractory/Relapsed Myeloma" . : 39
January 2006 Dispenzeri A, Loe MJ,Geyer, SM, Allred JB, Armitage JO, Camoriano JK, Dogan A, Menke DM, Habermann TM."A Prognostic Model of 114 Patients with Castleman's Disease" . : 798
January 2006 Ansell SM,Geyer, SM, Hurvits S, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Timmerman J."Phase I/II Study of Ipilimumab (MDX-010), and Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-hodgkins Lymphoma" . : 2729
January 2006 Tschumper RC,Geyer, SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Call TG, Jelinek DF."D Gene Usage Predicts Clinical Outcome in Patients with Low Rai Risk Unmuted B-CLL" . : 2779
January 2006 Thompson CA, Wang S, Maurer MJ, Habermann TM, Severson RK, Rothman N, Lynch CF, Davis S, Morton LM, Cozen W, Hartage P,Geyer, SM, Chanock S, Cerahn JR."Host Immunogenetic Single Nucleotide Polymorphisms (SNPs) Predict Overall Survival in Small Lymphocytic lymphoma" . : 2396
January 2006 Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Greipp PR, Witzig TE, Kumar S,Geyer, SM, Moon-Tasson LL, Rajkumar SV, Donaovan KA."Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therpaies Than Apoptosis Inducing Agents" . : 3500
January 2006 Geyer, SM, Morton LM, Habermann TM, Allmer C, Davis S, Cozen W, Saverson RK, Lynch CF, Wang S, Mauerer MJ, Hartge P, Cerhan JR."Smoking and obesity Survival in Non-hodgkin Lymphoma (NHL): A Population-based Study" . : 4649
January 2006 Cerhan JR, Wang S, Mauerer MJ, Ansell SM,Geyer, SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Chanock S, Habermann TM, Hartge P."Cytokine Gene Polymorphisms and Overall Survival in Follicular Lymphoma: Results from a Large Population Based Study" . : 820
January 2006 Browning RE, Lucas DM,Geyer, SM, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE."Expressions of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-cell Chronic Lymphocytic Leukemia" . : 2792
January 2007 Mauerer M,Geyer, SM, Wang S, Habermann T, Ansell S, Hartge P, Cerhan J."Epidemiological Methods, Risk Factors, and Incidenc" . : 47
January 2007 Johnston PB, Ansell Sm, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Micallef In, Porrata LF, LaPlant BR,Geyer, SM, Witzig TE."A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) for Patients with Relapsed or Refactory Lymphoma" . : 8055
January 2007 Cullings HM, Furukawa K,Geyer, SM,."Geospatial Hotspot Analysis vs. Directional Analysis of Radiation Health Effects Among Atomic Bomb Survivors" .
January 2007 Palmer S, Hanson CA, Zent CS, Porrata LF, LaPlant BR,Geyer, SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay BF, Shanafelt TD."The Prognostic Importance of T and NK-cells in a Consecutive Series of Newly Diagnosed Patients with Chronic lymphocytic Leukemia" . : 3080
January 2007 Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Greipp PR, Witzig TE, Kumar S, Geyer, SM, Donovan KA."Prevention of Active Mulitple Myeloma (MM) Using Il-1 Receptor Antagonist (Il-11ra) and Low-dose Dexamtheasone (Dex) and Monitoring the High Sensitivity C-Reactive Protien (hsCRP)" . : 8105
January 2007 Habermann TM, Link BK, Maurer MJ, Wooldridge JE,Geyer, SM, Macon WR, Allmer C, Ansell SM, Witzig TE, Weiner GJ, Cerhan JR."The IPI Predicts Outcome in Patients with Diffuse Large B-cell Lymphoma (DLBCL) Treated with Immunochemotherapy: A Report of the University of Iowa/Mayo Clinic SPORE" . : 1279
January 2007 Zent CS, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Secreto CR, Bowen DA,Geyer, SM, Kabat BF, LaPlant BR, Wu W, Kay NE."Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL)" . : 2050
January 2008 Takahashi I,Geyer, SM, Fujiwara S, Nishi N, Ohshita T, Takahashi T, Matusmoto M."Lifetime Risk of Stroke in Atomic Bomb Survivors" .
January 2008 Lust J, Lacy M, Zeldenrust S, Dispenzieri A, Gertz M, Greipp P, Wtizig T, Kumar S,Geyer, SM, Rajkumar V, Donovan K,."Smoldering/Indolent Multiple Myeloma (SMM/IMM) Increased Time to Progression and Can Be Indentified with the Hight Sensitivity C-reactive Protein (hsCRPP" . : 5530
January 2008 Geyer, SM, Grant E, Neriish K, Cullings H, Funamoto S, Colongne J."Nested Case-Control Sample Selection with Counter Matching on Exposure" .
January 2010 Gertz MA, Geyer SM, Kahl BS, Badros A, Reeder C, Erlichman C,."A Phase I Trial of Oblimersen Sodium (G3139) for Relapsed or Refactory Waldenstrom Macroglobulinemia" . : 2407
January 2010 Rajkumar SV, Hayman S, Lacy MQ, Dispenzieri A,Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell RJ, Kyle RA, Witzig TE, Gertz MA."Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma" . : 781

Presentations

"Forecasting and Turning Points in Enviornmental Time Series Under Asymmetric Loss." Presented at ENAR Meeting, Pittsburgh. (March 1998)

"Predicting Spatial Hotspot Regions." Presented at Economic and Statistics Office, Price Waterhouse Coopers, . (September 1999)

"Predicting Spatial Hotspot Regions." Presented at Mayo Clinic, JP|JPN. (November 1999)

"Differences in Overall Survival in Lung Cancer Patients by Prognostic Factors." Presented at Lung Cancer Disease Oriented Group Meeting, Rochester, MN. (April 2001)

"Overview of Spatial Statistics and it's Applications." Presented at Mayo Clinic, Rochester, MN. (January 2001)

"Single stage Phase II design with an Interim Analysis: An Alternative to the Two Stage Design." Presented at Society for Clinical Trials, Denver, CO. (May 2001)

"Quality of Life in Lung Cancer Trials." Presented at Quality of Life Committee meeting, . (October 2001)

"Challenges and Triumphs in Establishing a Mulit-Institution Clinical Trials." Presented at Phase 2 Consortium, Rochester, MN. (May 2002)

"Challenges and Trimphs in Establishing a Multi-Institution Clinical Trials Consortium Presentation." Presented at Society for Clinical Trials, Arlington, VA. (May 2002)

"Biostatistics in Lung Cancer Research: An Overview." Presented at Mayo Clinic Lung Research Group Retreat, Rochester, MN. (August 2002)

"Cost of Conducting Industry-Driven Clinical Trials." Presented at Mayo Clinic Center Clinical Research Committee, Rochester, MN. (April 2002)

"Common Data Elements Development for Myeloma Trials: A Joint Project of the National cooperative Cancer Clinical Trials Groups in NCI." Presented at International Workshop in Multiple Myeloma Meeting, Salamanca, ES|ESP. (May 2003)

"Methods for Evaluating T Cell Repertoire (TcR) via CDR3 Spectratyping Analysis." Presented at Mayo Clinic, Rochester, MN. (May 2004)

"Methods for Evaluating T Cell Repertorie (TcR) via CDR3 Spectratyping Analysis." Presented at Joint Statistical Meetings ASA, Toronto, CA|CAN. (August 2004)

"Phase II Study of PS-341 (Bortezomib) in the Treatment of Metastatic Malignant Melanoma (MMM)." Presented at American Society of Clinical Oncology Annual Meeting, New Orleans, LA. (June 2004)

"Multiple Comparison: A Clinical Trials Example." Presented at Mayo Clinic, Rochester, MN. (June 2004)

"Incorporating Interim Analyses and/or Historical Controls into Flexible Screening Trials." Presented at Society for Clinical Trials, Portland, OR. (May 2005)

"Methods for Evaluating T-cell Receptor (TcR) Repertorie via CDR3 Spectratyping Analysis." Presented at American Association for Cancer Research, Anaheim, CA. (April 2005)

"Methods Evaluating T Cell Receptor Repertorie Data." Presented at Radiation Effects Research Foundation, Hiroshima, JP|JPN. (October 2006)

"An Approach for Assesing Multi-SNP association with Survival in a Candidate Gene Setting." Presented at Hiroshima Statistics Study Group, JP|JPN. (October 2007)

"Relaistic Considerations and Applications for Comparative Clinical Trials." Presented at Society for Clincial Trials, Montreal, QC, CA|CAN. (May 2007)

"Lifetime Risk Analysis of Stroke in the Adult Health Study." Presented at Radiation Effects Research Foundation, Department of Statistics, JP|JPN. (September 2008)

"constraints and issues related to analyzing environmental and exposure data.." Presented at Environmental Science and Statistics Short Course, Fukuoka, JP|JPN. (September 2008)

"Nested Case-control Sample Selection with Counter Matching on Exposure." Presented at The 21st International L H Gray Conference, The Society for Radiological Protection, Edinburgh. (June 2008)

"design of early phase clinical trials as well as their corresponding constraints and challenges in their design and implementation.." Presented at Graduate course in Epidemiology offered through the School of Public Health, Columbus, OH, US|USA. (June 2010)

"Multi-part series on early phase clinical trial design." Presented at The Ohio State University, Divisions of Hematology and Oncology, Columbus, Ohio. (July 2010)

"Analysis Update of Clonal B-cell CD38 and Immunoglobin Variable Region Sequence Status in Relation to Clinical Outcomes for B-CLL." Presented at B-Cell Lymphoproliferative Disorders II Internationla Meeting, Amersterdam, NL|NLD. (January 2010)

"Novel Clinical Trial Designs." Presented at The Ohio State University, International Thyroid Oncology Group Annual Meeting, . (April 2012)

 

Professional Activities

2000 - 2002 Radiation Oncology Sub-specialty Conference. Mayo Clinic.